Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study

Trial Profile

Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Microscopic polyangiitis; Wegener's granulomatosis
  • Focus Adverse reactions
  • Acronyms RAVELOS
  • Most Recent Events

    • 17 Oct 2017 Status changed from recruiting to discontinued.
    • 25 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top